日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

International neuroblastoma risk group consortium: a model of networking for rare cancers

国际神经母细胞瘤风险组联盟:罕见癌症网络模式

Cohn, Susan L; London, Wendy B; Schleiermacher, Gudrun; Moreno, Lucas; Ambros, Inge M; Ambros, Peter F; Bagatell, Rochelle; Popovic, Maja Beck; Beiske, Klaus Hermann; Berthold, Frank; Birz, Suzi; Brisse, Hervé J; Brodeur, Garrett M; Brock, Penelope R; Burchill, Susan; Eggert, Angelika; Federico, Sara M; Fischer, Matthias; Furner, Brian T; Hero, Barbara; Machin, David; Kamijo, Takehiko; Matthay, Katherine K; Nakagawara, Akira; Naranjo, Arlene; Pötschger, Ulrike; Valteau-Couanet, Dominique; Watkins, Michael T; Irwin, Meredith S; Volchenboum, Samuel L; Park, Julie R; Pearson, Andrew D J

Simplified dosimetry using two-time-point kinetic modeling of (124)I-MIBG PET for (131)I-MIBG therapy in neuroblastoma

利用 (124)I-MIBG PET 的双时间点动力学模型简化剂量测定,用于神经母细胞瘤的 (131)I-MIBG 治疗

Wang, Yiran; Huh, Yoonsuk; Matthay, Katherine K; Vo, Kieuhoa T; Pampaloni, Miguel H; DuBois, Steven G; Seo, Youngho

Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

(131)I-间碘苄胍联合Dinutuximab±Vorinostat治疗复发或难治性神经母细胞瘤患者的I期研究:神经母细胞瘤治疗新方法试验

Cash Thomas, Marachelian Araz, DuBois Steven G, Chi Yueh-Yun, Baregamyan Anahit, Groshen Susan G, Jonus Hunter C, Shamirian Anasheh, Crowley Mary, Goodarzian Fariba, Acharya Patricia T, Pawel Bruce, Erbe Amy K, Shahi Ankita, Zaborek Jen, Kennedy Eleanor, Asgharzadeh Shahab, Villablanca Judith G, Pinto Navin, Weiss Brian D, Mosse Yael P, Desai Ami V, Macy Margaret E, Granger Meaghan, Vo Kieuhoa T, Sondel Paul M, Matthay Katherine K, Park Julie R, Goldsmith Kelly C

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

一项针对复发性神经母细胞瘤患者的高剂量DFMO、塞来昔布、环磷酰胺和拓扑替康联合治疗的I期研究:一项神经母细胞瘤治疗新方法试验

Hogarty, Michael D; Ziegler, David S; Franson, Andrea; Chi, Yueh-Yun; Tsao-Wei, Denice; Liu, Kangning; Vemu, Rohan; Gerner, Eugene W; Bruckheimer, Elizabeth; Shamirian, Anasheh; Hasenauer, Beth; Balis, Frank M; Groshen, Susan; Norris, Murray D; Haber, Michelle; Park, Julie R; Matthay, Katherine K; Marachelian, Araz

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with (131)I-MIBG therapy in high-risk neuroblastoma

在(131)I-MIBG 疗法治疗高危神经母细胞瘤时,Aurora 激酶 A 抑制剂可增强 DNA 损伤和肿瘤细胞死亡。

Kumar, Prerna; Koach, Jessica; Nekritz, Erin; Mukherjee, Sucheta; Braun, Benjamin S; DuBois, Steven G; Nasholm, Nicole; Haas-Kogan, Daphne; Matthay, Katherine K; Weiss, William A; Gustafson, Clay; Seo, Youngho

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma

去甲肾上腺素转运体和囊泡单胺转运体2的肿瘤表达作为复发/难治性神经母细胞瘤患者对(131)I-MIBG治疗反应的预测因子

Batra, Vandana; Gikandi, Ajami; Pawel, Bruce; Martinez, Daniel; Granger, M Meaghan; Marachelian, Araz; Park, Julie R; Maris, John M; Vo, Kieuhoa T; Matthay, Katherine K; DuBois, Steven G

Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group

神经母细胞瘤相关眼阵挛-肌阵挛-共济失调综合征患者的远期认知和适应性结局:儿童肿瘤协作组的报告

Kumar, Prerna; Willard, Victoria W; Embry, Leanne; Naranjo, Arlene; LaBarre, Brian; Matthay, Katherine K; de Alarcon, Pedro A

Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531

对接受基于反应和生物学疗法的中危神经母细胞瘤患者进行长期随访:来自儿童肿瘤协作组研究 ANBL0531 的报告

Barr, Erin K; Naranjo, Arlene; Twist, Clare J; Tenney, Sheena C; Schmidt, Mary Lou; London, Wendy B; Gastier-Foster, Julie; Adkins, E Stanton; Mattei, Peter; Handler, Michael H; Matthay, Katherine K; Park, Julie R; Maris, John M; Desai, Ami V; Cohn, Susan L

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

劳拉替尼联合或不联合化疗治疗ALK驱动的难治性/复发性神经母细胞瘤:1期临床试验结果

Goldsmith, Kelly C; Park, Julie R; Kayser, Kimberly; Malvar, Jemily; Chi, Yueh-Yun; Groshen, Susan G; Villablanca, Judith G; Krytska, Kateryna; Lai, Lillian M; Acharya, Patricia T; Goodarzian, Fariba; Pawel, Bruce; Shimada, Hiroyuki; Ghazarian, Susan; States, Lisa; Marshall, Lynley; Chesler, Louis; Granger, Meaghan; Desai, Ami V; Mody, Rajen; Morgenstern, Daniel A; Shusterman, Suzanne; Macy, Margaret E; Pinto, Navin; Schleiermacher, Gudrun; Vo, Kieuhoa; Thurm, Holger C; Chen, Joseph; Liyanage, Marlon; Peltz, Gerson; Matthay, Katherine K; Berko, Esther R; Maris, John M; Marachelian, Araz; Mossé, Yael P

Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group

儿童肿瘤协作组报告:诊断和诱导治疗结束时居里评分对转移性高危神经母细胞瘤联合大剂量化疗和自体移植治疗的影响

Streby, Keri A; Parisi, Marguerite T; Shulkin, Barry L; LaBarre, Brian; Bagatell, Rochelle; Diller, Lisa; Grupp, Stephan A; Matthay, Katherine K; Voss, Stephan D; Yu, Alice L; London, Wendy B; Park, Julie R; Yanik, Gregory A; Naranjo, Arlene